FDA
-
-
-
-
-
-
-
Cullinan Therapeutics receives FDA orphan drug status for leukemia drug
-
-
-
-
-
-
-
Cullinan Therapeutics outlines 2026 milestones, reports $439M cash
-
-
-
-
-
-
-
Taiho Oncology, partners begin rolling FDA submission for lung cancer drug
-
-
-
-
-
-
-
Taiho Oncology and Cullinan to present zipalertinib data at lung cancer conference
-
-
-
-
-
-
-
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Pri
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
-
328,710 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

